Related Experiment Video
Updated: May 8, 2026

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
Published on: July 25, 2020
Current phase II clinical data for ridaforolimus in cancer
Anna Spreafico1, Helen J Mackay
1Princess Margaret Hospital, Division of Medical Oncology and Hematology , 610 University Avenue, Toronto, Ontario, M5G 2M9 , Canada +1 416 846 2253 ; +1 416 946 6546 ; Helen.Mackay@uhn.ca.
Introduction:
The PI3K/AKT/mammalian target of rapamycin (mTOR) pathway plays a critical role in controlling cellular metabolism, proliferation and cell cycle regulation. Constitutive activation of this pathway has been demonstrated in many tumor types. Targeting the PI3K/AKT/mTOR pathway is of increasing therapeutic interest.
Areas Covered:
Ridaforolimus belongs to a class of agents known as the rapalogs, first-generation mTOR inhibitors, which inhibit mTORC1, a part of the mTOR complex. Both oral and intravenous formulations of this agent have been tested in Phase II clinical trials for the treatment of solid tumors and hematologic malignancies. Promising results have been seen in endometrial cancer and soft tissue and bone sarcomas.
Expert Opinion:
This article summarizes the current clinical and biological data on the use of ridaforolimus emerging from these Phase II studies, and provides potential advantages and drawbacks of the mTOR inhibitors in the current clinical practice.
More Related Videos
08:12Detection of a Circulating MicroRNA Custom Panel in Patients with Metastatic Colorectal Cancer
Published on: March 14, 2019
05:56Evaluation of the Feasibility, Safety, and Accuracy of an Intraoperative High-intensity Focused Ultrasound Device for Treating Liver Metastases
Published on: January 9, 2019
Related Concept Videos
Clinical Trials: Overview
Clinical Trials
There are four phases in a clinical trial. A phase one...
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
Treatment Resistant Cancers
Inhibition of Cdk Activity
Targeted Cancer Therapies
There are several types of targeted therapies against specific...